Durvalumab is a Monoclonal Antibody owned by AstraZeneca, and is involved in 468 clinical trials, of which 131 were completed, 310 are ongoing, and 27 are planned.

Durvalumab acts as CD274 (Programmed Cell Death 1-Ligand 1 or PDL-1) inhibitor. The drug candidate blocks the interaction between PD-L1 and its receptors, PD-1 and CD80 (PD-1). This blockade may help to overcome the immunosuppressive effects of PD-L1 signaling in anti-tumor T cells. programmed death receptor 1 (PD-1) negatively regulates T-cell receptor (TCR) signaling. Upon ligating its receptor, PD-L1 decreases TCR-mediated proliferation and cytokine production.

The revenue for Durvalumab is expected to reach a total of $77bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Durvalumab NPV Report.

Durvalumab was originated by MedImmune and is currently owned by AstraZeneca.

Durvalumab Overview

Durvalumab (MEDI-4736, Imfinzi, Fidursi, Imfinzio) a programmed death-ligand 1 (PD-L1) blocking antibody. It is formulated as solution and concentrate solution for intravenous route of administration. Imfinzi is indicated as maintenance therapy after definitive chemoradiation therapy (CRT) in locally-advanced (Stage III), unresectable non-small cell lung cancer (NSCLC). and for the treatment of patients with unresectable, Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (CRT), 1st-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) in combination with standard-of-care (SoC) chemotherapies, etoposide plus either carboplatin or cisplatin (platinum-etoposide), and adult patients with locally advanced or metastatic biliary tract cancer (BTC) in combination with gemcitabine and cisplatin.

It is under development for the treatment of advanced or metastatic papillary renal cell carcinoma, poorly differentiated thyroid carcinoma, anaplastic thyroid cancer, follicular thyroid cancer, medullary thyroid cancer and papillary thyroid cancer, HER2 negative metastatic breast cancer, esophageal squamous cell carcinoma, secondary central nervous system lymphoma and secondary diffuse large B-cell lymphoma (DLBCL), pulmonary sarcomatoid carcinoma, bile duct cancer, non-small cell lung cancer, metastatic colorectal cancer, glioblastoma multiforme, recurrent head and neck cancer squamous cell carcinoma, esophageal squamous cell carcinoma (ESCC), head and neck cancer squamous cell carcinoma, hepatocellular carcinoma, metastatic biliary tract cancer, esophageal cancer, Epstein-Barr virus positive (EBV+) nasopharyngeal carcinoma, adenocarcinoma of the gastro-esophageal junction, renal cell carcinoma, ovarian cancer, metastatic hormone refractory (castration resistant, androgen-independent) prostate cancer, muscle invasive bladder cancer (MIBC), mycosis fungoides, sezary syndrome, malignant pleural mesothelioma, myelodysplastic syndrome, small-cell lung cancer, non-muscle invasive bladder cancer (NMIBC) (superficial bladder cancer), endometrial cancer, diffuse large b-cell lymphoma, primary mediastinal B-cell lymphoma, follicular thyroid cancer, oropharyngeal cancer, human papillomavirus (HPV) associated cancer, t-cell lymphomas, primary mediastinal b-cell lymphoma, germ cell tumors, soft tissue sarcoma, transitional cell carcinoma (urothelial cell carcinoma), b-cell chronic lymphocytic leukemia, lymphoma, refractory multiple myeloma, relapsed multiple myeloma, B-cell non-Hodgkin lymphoma, breast cancer, triple-negative breast cancer, endometrial cancer, hormone-sensitive prostate cancer, esophageal cancer, primary CNS lymphoma, anaplastic large cell lymphoma, small-cell lung cancer, malignant pleural mesothelioma, fallopian tube cancer, peritoneal cancer, oropharyngeal cancer, metastatic breast cancer, ovarian cancer, metastatic adenocarcinoma of the pancreas, vulvar cancer, vaginal cancer, human papillomavirus (HPV) associated cancer, gastric cancer, pancreatic ductal adenocarcinoma, esophageal cancer, melanoma, oral cavity (mouth) cancer, leiomyosarcoma, gallbladder cancer, metastatic melanoma, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, metastatic biliary tract cancer, papillary renal cell carcinoma, metastatic renal cell carcinoma, transitional cell carcinoma (urothelial cell carcinoma), angiosarcoma, dedifferentiated liposarcoma, osteosarcoma, bladder carcinoma, ureter cancer, urethral cancer, chronic lymphocytic leukemia (CLL).

It was also under development for metastatic cervical cancer, neuroendocrine tumor, multiple myeloma (Kahler disease) as firstline therapy, relapsed and refractory multiple myeloma, diffuse large B-cell lymphoma, peripheral T-cell lymphomas (PTCL), Post-Polycythemia Vera myelofibrosis (PPV-MF), post-essential thrombocythemia myelofibrosis (POST-ET MF), primary myelofibrosis, B-cell chronic lymphocytic leukemia, lymphoma and recurrent head and neck cancer squamous cell carcinoma (first line therapy) and unspecified cancer.

AstraZeneca Overview

AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The COVID-19 Vaccine AstraZeneca has been approved for conditional marketing or emergency use. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.

The company reported revenues of (US Dollars) US$37,417 million for the fiscal year ended December 2021 (FY2021), an increase of 40.6% over FY2020. In FY2021, the company’s operating margin was 2.8%, compared to an operating margin of 19.4% in FY2020. In FY2021, the company recorded a net margin of 0.3%, compared to a net margin of 12% in FY2020. The company reported revenues of US$10,982 million for the third quarter ended September 2022, an increase of 2% over the previous quarter.

Quick View – Durvalumab

Report Segments
  • Innovator (NME)
Drug Name
  • Durvalumab
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.